Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab

References

• Varga Z, Noske A, Ramach C, et al. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer. 2013;13:615.
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Yoo M, Unni SK, et al. Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer (Dove Med Press)). 2014;6:169–177.
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–2648.
   PubMed Web of Science ®Google Scholar
• Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;18(4):CD006243.
   Google Scholar
• Lidbrink E, Chmielowska E, Otremba B, et al. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat. 2019;174(1):187–196.
   PubMed Web of Science ®Google Scholar
• Mohan N, Shen Y, Endo Y, et al. Trastuzumab, but not pertuzumab, dysregulates her2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016;15(6):1321–1331.
   PubMed Web of Science ®Google Scholar
• ElZarrad MK, Mukhopadhyay P, Mohan N, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One. 2013;8(11):e79543.
   PubMed Web of Science ®Google Scholar
• Yavas O, Yazici M, Eren O, et al. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly. 2007;137(39-40):556–558.
   PubMed Web of Science ®Google Scholar
• Garg A, Li J, Clark E, et al. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol. 2013;72(5):1133–1141.
   PubMed Web of Science ®Google Scholar
• Karaca M, Kocoglu H, Bilgetekin I, et al. Ventricular bigeminal rhythm associated with trastuzumab: a potential cardiac side effect. J Cancer Res Ther. 2018;14(Supplement):S536–S537.
   PubMed Web of Science ®Google Scholar
• Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study. Arch Med Sci. 2012;2(2):227–235.
   Web of Science ®Google Scholar
• Choe JC, Choi JH, Choi JH, et al. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer. Clin Cardiol. 2018;41(10):1308–1314.
   PubMed Web of Science ®Google Scholar
• Taylor CJ, Roalfe AK, Iles R, et al. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. BMJ Open. 2014;4(4):e004675.
   PubMed Web of Science ®Google Scholar
• Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56(526):327–333.
   PubMed Web of Science ®Google Scholar
• Banke A, Fosbol EL, Ewertz M, et al. Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail. 2019;7(3):217–224.
   PubMed Web of Science ®Google Scholar
• Ponde N, Bradbury I, Lambertini M, et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2018;168(3):631–638.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Cin Oncol. 2010;28(25):3910–3916.
   PubMed Web of Science ®Google Scholar
• Demissei BG, Finkelman BS, Hubbard RA, et al. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer. 2019;125(16):2762–2771.
   PubMed Web of Science ®Google Scholar
• D'Errico MP, Grimaldi L, Petruzzelli MF, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):e239–e246.
   PubMedGoogle Scholar
• Bisoc A, Ciurescu D, Radoi M, et al. Elevations in high-sensitive cardiac troponin t and n-terminal prohormone brain natriuretic peptide levels in the serum can predict the development of anthracycline-induced cardiomyopathy. Am J Ther. 2020;27(2):e142–e150.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205.
   PubMed Web of Science ®Google Scholar
• Kosalka P, Johnson C, Turek M, et al. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. Curr Oncol. 2019;26(3):e314–e321.
   PubMed Web of Science ®Google Scholar
• Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792–3799.
   PubMed Web of Science ®Google Scholar
• Mason JW, Badilini F, Vaglio M, et al. A fundamental relationship between intraventricular conduction and heart rate. J Electrocardiol. 2016;49(3):362–370.
   PubMed Web of Science ®Google Scholar
• Gavazzi A, De Maria R, Grosu A, et al. Screening of asymptomatic left ventricular systolic dysfunction in a population sample at high cardiovascular risk in Lombardy (Italy): the DAVID-Berg study. G Ital Cardiol (Rome). 2014;15(5):313–322.
   PubMedGoogle Scholar
• Boffa U, McGrady M, Reid CM, et al. SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace. Aust Health Rev. 2017;41(2):121–126.
   PubMed Web of Science ®Google Scholar
• McGrady M, Reid CM, Shiel L, et al. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF). Int J Cardiol. 2013;169(2):133–138.
   PubMed Web of Science ®Google Scholar